Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

Sara Alosaimy, Sarah C.J. Jorgensen, Abdalhamid M. Lagnf, Sarah Melvin, Ryan P. Mynatt, Travis J. Carlson, Kevin W. Garey, David Allen, Veena Venugopalan, Michael Veve, Vasilios Athans, Stephen Saw, Christine N. Yost, Susan L. Davis, Michael J. Rybak

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

Original languageEnglish (US)
Article numberofaa051
JournalOpen Forum Infectious Diseases
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2020
Externally publishedYes

Keywords

  • Carbapenem-resistant Enterobacteriaceae
  • Gram-negative infections
  • Meropenem-vaborbactam
  • Multidrug-resistant

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections'. Together they form a unique fingerprint.

Cite this